Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment
Wojciech Ciesielski,
Izabela Kupryś-Lipińska,
Anna Kumor-Kisielewska,
Oliwia Grząsiak,
Julia Borodacz,
Sebastian Niedźwiecki,
Piotr Hogendorf,
Adam Durczyński,
Janusz Strzelczyk,
Alicja Majos
Affiliations
Wojciech Ciesielski
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Izabela Kupryś-Lipińska
Internal Medicine, Asthma and Allergy Department, Medical University of Łódź, 90-419 Łódź, Poland
Anna Kumor-Kisielewska
Department of Pneumology and Allergy, Medical University of Łódź, 90-419 Łódź, Poland
Oliwia Grząsiak
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Julia Borodacz
Students’ Scientific Association in General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Sebastian Niedźwiecki
Department of Surgical Oncology, Medical University of Łódź, 90-419 Łódź, Poland
Piotr Hogendorf
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Adam Durczyński
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Janusz Strzelczyk
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
Alicja Majos
General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland
(1) Background: The importance of total eosinophil count in peripheral blood (EOS) as a type 2 inflammation marker is known to be fundamental in asthma, chronic sinusitis, and vasculitis. In cancer, despite their questionable antiproliferative effect, their role remains unclear. Our purpose was to describe the relationship between baseline blood EOS and overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) patients. (2) Methods: We retrospectively analyzed data from 137 adult patients who underwent surgical treatment for pancreatic ductal adenocarcinoma (PDAC) between the years 2012 and 2019. Patients with no recent history of systemic steroid use and without intraoperative metastases were included. Patients were categorized into two groups based on EOS (≥0.1 G/l and p = 0.035 and HR = 1.57, p = 0.021). (4) Conclusions: Peripheral eosinophilia seems to be a potential independent prognostic factor. Further studies are necessary to confirm this hypothesis, since our findings suggest that type 2 inflammation may be the factor directly or indirectly lengthening the survival of patients with PDAC.
